Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so. Officers, directors, and beneficial owners have shelled out more than $10 million on each of the following four biotech stocks.
Wall Street expectations for these stocks are huge for the coming year, though some have seen falling share prices so far this year. Let’s take a quick look at these transactions.
This post originally appeared at 24/7 Wall St.